Association between conditioning intensity and height growth after allogeneic hematopoietic stem cell transplantation in children.
conditioning intensity
growth
hematopoietic stem cell transplantation
late effects
pediatrics
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
revised:
15
06
2023
received:
21
04
2023
accepted:
02
07
2023
medline:
15
9
2023
pubmed:
12
7
2023
entrez:
12
7
2023
Statut:
ppublish
Résumé
The present study aimed to examine the association between the conditioning intensity and height growth in pediatric patients who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT). We reviewed the clinical records of 89 children with malignant diseases who underwent initial allo-HSCT between 2003 and 2021. Height measurements were standardized using standard height charts prepared by the Japanese Society for Pediatric Endocrinology to calculate standard deviation score (SDS). We defined short stature as a height SDS less than -2.0 in that reference. Myeloablative conditioning (MAC) comprised total-body irradiation at more than 8 Gy and busulfan administration at more than 8 mg/kg (more than 280 mg/m A total of 58 patients underwent allo-HSCT with MAC, and 31 patients received allo-HSCT with RIC. There were significant differences in the height SDS at 2 and 3 years after allo-HSCT between MAC and RIC group (-1.33 ± 1.20 vs. -0.76 ± 1.12, p = 0.047, -1.55 ± 1.28 vs. -0.75 ± 1.11, p = 0.022, respectively). Multivariate logistic regression analysis with the adjustments for potential confounding factors of patients less than 10 years of age at allo-HSCT and chronic graft-versus host disease demonstrated that MAC regimen was associated with a markedly increased risk of a short stature at 3 years after allo-HSCT (adjusted odds ratio, 5.61; 95% confidence interval, 1.07-29.4; p = 0.041). The intensity of conditioning regimen may be associated with short statures after allo-HSCT.
Sections du résumé
BACKGROUND
The present study aimed to examine the association between the conditioning intensity and height growth in pediatric patients who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT).
METHODS
We reviewed the clinical records of 89 children with malignant diseases who underwent initial allo-HSCT between 2003 and 2021. Height measurements were standardized using standard height charts prepared by the Japanese Society for Pediatric Endocrinology to calculate standard deviation score (SDS). We defined short stature as a height SDS less than -2.0 in that reference. Myeloablative conditioning (MAC) comprised total-body irradiation at more than 8 Gy and busulfan administration at more than 8 mg/kg (more than 280 mg/m
RESULTS
A total of 58 patients underwent allo-HSCT with MAC, and 31 patients received allo-HSCT with RIC. There were significant differences in the height SDS at 2 and 3 years after allo-HSCT between MAC and RIC group (-1.33 ± 1.20 vs. -0.76 ± 1.12, p = 0.047, -1.55 ± 1.28 vs. -0.75 ± 1.11, p = 0.022, respectively). Multivariate logistic regression analysis with the adjustments for potential confounding factors of patients less than 10 years of age at allo-HSCT and chronic graft-versus host disease demonstrated that MAC regimen was associated with a markedly increased risk of a short stature at 3 years after allo-HSCT (adjusted odds ratio, 5.61; 95% confidence interval, 1.07-29.4; p = 0.041).
CONCLUSION
The intensity of conditioning regimen may be associated with short statures after allo-HSCT.
Identifiants
pubmed: 37434385
doi: 10.1002/cam4.6336
pmc: PMC10501226
doi:
Substances chimiques
Busulfan
G1LN9045DK
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
17018-17027Informations de copyright
© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Blood. 2007 Nov 15;110(10):3784-92
pubmed: 17671231
Blood. 2010 Nov 25;116(22):4439-43
pubmed: 20716774
Int J Hematol. 2010 Jul;92(1):95-104
pubmed: 20577841
Clin Pediatr Endocrinol. 2016 Apr;25(2):71-6
pubmed: 27212799
Blood. 2003 May 1;101(9):3373-85
pubmed: 12511420
J Natl Cancer Inst. 2020 Oct 1;112(10):994-1002
pubmed: 32123906
Bone Marrow Transplant. 2006 Sep;38(6):427-32
pubmed: 16878146
Lancet Oncol. 2020 Mar;21(3):421-435
pubmed: 32066543
Clin Endocrinol (Oxf). 2023 Feb;98(2):202-211
pubmed: 36156811
Bone Marrow Transplant. 2016 Jul;51(7):980-4
pubmed: 26974276
Pediatr Blood Cancer. 2008 Jan;50(1):1-8
pubmed: 17668859
Lancet Haematol. 2015 Mar;2(3):e91-100
pubmed: 26687803
N Engl J Med. 2016 Mar 3;374(9):833-42
pubmed: 26761625
Theor Biol Med Model. 2014 Oct 13;11:44
pubmed: 25312098
Blood. 2011 Aug 4;118(5):1413-20
pubmed: 21652685
Endocr Rev. 2008 Aug;29(5):535-59
pubmed: 18436706
Stat Med. 1992 Jul;11(10):1305-19
pubmed: 1518992
Blood. 2005 Oct 1;106(7):2592-3; author reply 2593
pubmed: 16172255
Biol Blood Marrow Transplant. 2015 Apr;21(4):620-4
pubmed: 25246296
Bone Marrow Transplant. 2009 Apr;43(8):637-42
pubmed: 19011662
Nat Rev Cancer. 2014 Jan;14(1):61-70
pubmed: 24304873
Blood. 1999 Jun 15;93(12):4109-15
pubmed: 10361107
Cancer Treat Rev. 2009 Nov;35(7):616-32
pubmed: 19640651
Blood. 2005 Feb 1;105(3):1348-54
pubmed: 15454481
Lancet Oncol. 2012 Oct;13(10):1035-44
pubmed: 22959335
Int J Hematol. 2010 Jun;91(5):865-76
pubmed: 20467848
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Cancer Med. 2023 Aug;12(16):17018-17027
pubmed: 37434385
Cancer. 2020 Oct 1;126(19):4379-4389
pubmed: 32725630
Bone Marrow Transplant. 2012 May;47(5):684-93
pubmed: 21725370
Biol Blood Marrow Transplant. 2009 Dec;15(12):1628-33
pubmed: 19896087
Lancet. 2004 Jul 10-16;364(9429):156-62
pubmed: 15246728
Bone Marrow Transplant. 1986 Dec;1(2):151-7
pubmed: 3332129
Radiology. 1994 Apr;191(1):231-5
pubmed: 8134578